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Breast cancer (BC) is the leading cause of cancer-related deaths in women.
Chemoprevention of BC by using plant extracts is gaining attention. SM6Met, a well-
characterized extract of Cyclopia subternata with reported selective estrogen receptor
subtype activity, has shown tumor suppressive effects in a chemically induced BC model
in rats, which is known to be estrogen responsive. However, there is no information
on the estrogen sensitivity of the relatively new orthotopic model of LA7 cell-induced
mammary tumors. In the present study, the potential chemopreventative and side-effect
profile of SM6Met on LA7 cell-induced tumor growth was evaluated, as was the effects
of 17β-estradiol and standard-of-care (SOC) endocrine therapies, such as tamoxifen
(TAM), letrozole (LET), and fulvestrant (FUL). Tumor growth was observed in the tumor-
vehicle control group until day 10 post tumor induction, which declined afterward on
days 12–14. SM6Met suppressed tumor growth to the same extent as TAM, while
LET, but not FUL, also showed substantial anti-tumor effects. Short-term 17β-estradiol
treatment reduced tumor volume on days prior to day 10, whereas tumor promoting
effects were observed during long-term treatment, which was especially evident at
later time points. Marked elevation in serum markers of liver injury, which was further
supported by histological evaluation, was observed in the vehicle-treated tumor control,
TAM, LET, and long-term 17β-estradiol treatment groups. Alterations in the lipid profiles
were also observed in the 17β-estradiol treatment groups. In contrast, SM6Met did
not augment the increase in serum levels of liver injury biomarkers caused by tumor
induction and no effect was observed on lipid profiles. In summary, the results from the
current study demonstrate the chemopreventative effect of SM6Met on mammary tumor
growth, which was comparable to that of TAM, without eliciting the negative side-effects
observed with this SOC endocrine therapy. Furthermore, the results of this study also
showed some responsiveness of LA7-induced tumors to estrogen and SOC endocrine
therapies. Thus, this model may be useful in evaluating potential endocrine therapies for
hormone responsive BC.
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INTRODUCTION
Breast cancer (BC) is the most commonly diagnosed malignancy
in women worldwide and a leading cause of cancer-related death
in women. Approximately 80% of all diagnosed BCs express
the estrogen receptor (ER) and are dependent on estrogen for
proliferation (Lumachi et al., 2015). Estrogen stimulates the
growth of BC through ER-mediated mechanisms and formation
of genotoxic estrogen metabolites (Santen et al., 2015).
The goal of antihormonal therapy is to reduce ER signaling
by directly antagonizing or downregulating ER or indirectly
by reducing estrogen levels via inhibition of aromatase, a key
enzyme in estrogen synthesis. Standard-of-care (SOC) endocrine
therapies such as tamoxifen (TAM), a selective ER modulator
(SERM), and fulvestrant (FUL), a selective ER down-regulator
(SERD), interfere with ER signaling via direct effects on the
ER. TAM acts by competitively antagonizing estrogen binding
to the ER in the breast, while FUL accelerates ER degradation
thereby reducing cellular ERα levels (Nathan and Schmid,
2017). Alternatively, letrozole (LET), an aromatase inhibitor
(AI), indirectly disrupts ER signaling by blocking the conversion
of adrenal androgens to estrogen in non-ovarian tissues
(Fabian, 2007).
Tamoxifen is extensively used as first line endocrine therapy in
both pre- and post-menopausal women with hormone responsive
(ER+) BC (Dixon, 2014). AIs are used as a monotherapy in post-
menopausal women either as first or second line interventions
(Wong and Ellis, 2004), while in pre-menopausal women with
functional ovaries, AIs are used in conjunction with ovarian
suppression/ablation (Fabian, 2007). FUL on the other hand
is mostly used in the treatment of tumors that have become
refractory to TAM or LET (Lumachi et al., 2015). Although
these adjuvant endocrine options are still the mainstay for the
treatment of ER-positive BC, de novo or acquired resistance (30–
40% in patients receiving adjuvant TAM therapy) and associated
side-effects (such as endometrial cancer, myocardial infarction,
hepatic injury, and renal dysfunction) limit the clinical usefulness
of these drugs (Hirsimäki et al., 2002; Kalender et al., 2007;
Puhalla et al., 2012; Yang et al., 2013; Gao et al., 2016).
Despite the advances in BC treatment, prevention if possible is
always better than treatment. Two SERMs, TAM and raloxifene,
have been approved by the FDA for BC chemoprevention,
although resistance and side-effects remain a huge challenge.
Hepatic injury is one of the most severe side-effects of long-term
use of TAM (Yang et al., 2013). There is a growing interest in
the use of natural compounds, specifically phytoestrogens (plant-
derived estrogen-like molecules), as potential chemopreventative
agents in mammary carcinogenesis (Mense et al., 2008; Kado
et al., 2012; Hwang and Choi, 2015). The consumption of
phytoestrogens is associated with a reduced incidence of pre-
menopausal BC in East Asian nations compared to the Western
World (Adlercreutz, 2002). Paradoxically, unlike estrogen,
phytoestrogens have demonstrated protective effects in BC via
multi-targeted actions such as: weak estrogenicity, reduction
in local estrogen production, antiproliferative and antioxidant
activities, epigenetic modifications and topoisomerase inhibition,
among others (Bolego et al., 2003; Rice and Whitehead, 2006).
In addition, low cytotoxicity to patients and lack of side-effects
in clinical trials have stimulated interest in the investigation of
the anticarcinogenic effects of phytoestrogens (Virk-Baker et al.,
2010).
Cyclopia (Family: Fabaceae) is a fynbos plant used as an
aromatic herbal tea called honeybush tea (Du Toit et al.,
1998). There are over 20 Cyclopia species indigenous to the
Eastern and Western Cape regions of South Africa (Schutte,
1997). Some documented beneficial properties of Cyclopia
include antimutagenic (Van der Merwe et al., 2006), antioxidant
(Marnewick et al., 2003), anticancer (Marnewick et al., 2005,
2009; Sissing et al., 2011), and antidiabetic (Larsen et al., 2008)
effects. In addition, there is documented evidence that Cyclopia is
a source of phytoestrogens (Verhoog et al., 2007).
Cyclopia subternata is one of the species primarily used
to produce honeybush tea. Many phenolic compounds with
health promoting benefits have been identified in C. subternata
(De Beer et al., 2012; Kokotkiewicz et al., 2012). SM6Met is
a well-characterized phytoestrogenic extract of C. subternata
with a comparable estrogenic potency to commercially available
phytoestrogenic nutraceuticals (Mfenyana et al., 2008; Mortimer
et al., 2015). Previous work from our group have shown that
SM6Met antagonizes estrogen-induced BC cell proliferation
in vitro (Visser et al., 2013). Although estrogen has a similar
affinity for both ER subtypes, studies in MCF7 BC cells suggest
that ERβ opposes the proliferative effects exerted by ERα (Ström
et al., 2004; Koehler et al., 2005). The preferential affinity of many
phytoestrogens for ERβ compared to ERα might thus be clinically
relevant in BC. SM6Met, for example, has displayed ER subtype
specific estrogenic activity namely, ERα antagonism and ERβ
agonism (Visser et al., 2013). In an immature rat uterotrophic
model, the lack of uterine growth and delayed vaginal opening
following treatment with the SM6Met extract provides additional
evidence for its anti-estrogenic and ERα antagonistic effect
(Visser et al., 2013). In addition, the inhibitory effects of
SM6Met on cell cycle progression have been documented
(Visser et al., 2016).
LA7 is a mammary adenocarcinoma cell line isolated
from 7,12-dimethylbenz[a]anthracene (DMBA)-induced BC rats
(Zucchi et al., 2007). The induction of mammary tumors with
LA7 cancer cells is a relatively new orthotopic method of
developing solid mammary gland tumors in immunocompetent
rats. The advantages of this model are the strong tumorigenic
properties of the cells and a relatively short duration, within 7–
10 days, of tumor development. This is a significantly shortened
experimental protocol compared to the 8–10 weeks of tumor
latency in chemically induced [methyl-N-nitrosourea (MNU)
and DMBA] mammary carcinogenic models (Abbasalipourkabir
et al., 2010; Karimian et al., 2015; Alvarado et al., 2017).
Not only is the LA7 model a faster method of tumor
induction, but it is also ideally suited for testing therapies
specifically targeting late stage carcinogenesis (progression)
while circumventing the earlier phases. Although the chemical
carcinogen models (DMBA and MNU) permit analysis of the
early stages of carcinogenesis (induction and promotion), they
are also suitable for the study of malignant progression or
the advanced stage of mammary cancers, however, the longer
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latency often required for development of tumors remain an
important limitation. Thus, the present model is particularly
useful for investigating suppressing agents that interfere with
later stages of carcinogenesis (progression) by simulating the
delay of the growth of existing occult breast tumors and as such
may be termed chemoprevention (Santen et al., 2017). The short
tumor latency of the LA7 model might also be advantageous
for a quicker assessment of potential endocrine therapies for
BC compared to the longer latency encountered in hormone-
dependent MNU and DMBA models.
To date, there is no information regarding the estrogen
responsiveness of LA7-induced mammary tumors. However, a
few available studies have demonstrated the ability of TAM
to suppress the growth of LA7 mammary tumors, suggesting
the endocrine responsiveness of this model (Syam et al., 2016;
Bakar et al., 2017). Although the presence of ERα is a well-
established predictor of response to TAM treatment in BC (Droog
et al., 2013; Rondón-Lagos et al., 2016), evidence also exists that
some ERα-negative tumors benefit from adjuvant TAM treatment
(Gruvberger-Saal et al., 2007; Manna and Holz, 2016; Rondón-
Lagos et al., 2016).
Several phytochemicals with documented anti-cancer
effects have been identified in SM6Met (Louw et al., 2013).
A combinational approach, involving the use of more than
one bioactive dietary compound in chemoprevention or
cancer therapy, holds great promise to progress into clinical
chemoprevention trials especially if its efficiency is accompanied
with minimal side-effects (Saldanha and Tollefsbol, 2012).
A recent study from our group has shown that SM6Met, a
selective ER subtype modulator (SERSM), delays the growth of
mammary tumors in a chemical carcinogen (MNU) model that
is particularly known to be estrogen dependent (Visser et al.,
2016). Considering the relatively short tumor latency and lack
of information regarding the estrogen responsiveness of LA7-
induced mammary tumors, in the present study, we examined
the dose-dependent chemopreventative effect of SM6Met, in this
model of mammary tumorigenesis and compared effects to that
of SOC endocrine therapies. In terms of toxicity, we also report
for the first time the effect of SM6Met on liver and kidney
function. Furthermore, this is the first study to report the effect
of estrogen treatment and SOC endocrine therapies, such as FUL
and LET, on tumor growth in this relatively new orthotopic
model of mammary tumorigenesis.
MATERIALS AND METHODS
Chemicals
All the solvents used for plant extraction and quantitative HPLC
analysis were of analytical grade and supplied by Merck Millipore,
S.A. Acetonitrile and acetic acid were supplied by Sigma-Aldrich
(South Africa). Protocatechuic acid, p-coumaric acid, 3-β-D-
glucopyranosyliriflophenone (IMG), hesperidin, mangiferin, and
scolymoside were purchased from Sigma-Aldrich (South Africa).
Eriocitrin was purchased from Extrasynthese (France)
and vicenin-2 was purchased from Phytolab (Germany).
Isomangiferin was purchased from Chemos GmbH (Germany).
3′,5′-Di-β-D-glucopyranosylphloretin (PDG) and 3-β-D-
glucospyranosyl-4-β-D-glucopyranosyloxyiriflophenone (IDG)
were isolated from Cyclopia subternata (unpublished results)
and Cyclopia genistoides (Beelders et al., 2014), respectively.
Castor oil, 17β-estradiol, and SOC endocrine drugs were
purchased from Sigma-Aldrich. All reagents for the estimation
of biochemical parameters were purchased from Horiba ABX
Pentra (Montpellier, France).
Preparation of Plant Extract
Dried plant material (leaves) of a C. subternata harvesting (M6;
harvested on 30 March 2004 from a commercial plantation at
Kanetberg farm near Barrydale, South Africa) was extracted
according to a previously described procedure (Mortimer et al.,
2015).
Briefly, 500 g finely pulverized, dried C. subternata leaves
were defatted with dichloromethane (2 L) by stirred extraction
over a period of 24 h. Following extraction, the plant material
was filtered, and the residue was air-dried overnight in a fume
cabinet at room temperature. This process was repeated four
times. Next, the air-dried, defatted plant material was subjected
to sequential extraction using three solvents (2 L each) in order
of increasing polarity (ethyl acetate, ethanol, and methanol).
The sequential extraction step in the sequence was performed
three times for 3 h per step. Before a solvent change was
made, the plant material was air-dried overnight in a fume
cabinet at room temperature. The filtrates of the final methanol
extraction step were retained, pooled, and the methanol extract
evaporated under vacuum (Büchi Rotavap, Switzerland) at 40◦C.
A small quantity of deionized water was added to the evaporated
extract and the extract was freeze-dried (Virtis Advantage Plus,
United States). The freeze-dried extract was ground with a pestle
and mortar to obtain a fine powder (60.2 g) that was stored in a
desiccator, protected from light, at room temperature. Batches of
SM6Met were prepared using the procedure described above and
a mixture of these batches was used for animal treatment.
Quantification of Phenolic Compounds in
SM6Met Using Quantitative HPLC
(qHPLC)
Stock solutions of SM6Met and standards were prepared in
DMSO and frozen at −20◦C until needed for analysis. Defrosted
extract and standards were appropriately diluted with water
for experimental analysis and ascorbic acid (Sigma-Aldrich)
was added to a final concentration of 9 mg/mL. The mixtures
were then filtered using Millex-HV syringe filters (Millipore,
United States) with a 0.45 µm pore size.
Analyses were performed on an Agilent 1200 HPLC
consisting of an in-line degasser, quaternary pump, autosampler,
column oven, and diode-array detector (DAD), controlled by
Chemstation software (Agilent Technologies, Santa Clara, CA,
United States). Separation was achieved on a Gemini-NX
C18 column (150 × 4.6 mm; 3 µm; 110 Å; Phenomenex,
United States), protected by a guard column (4 × 3.0 mm;
Phenomenex) of the same stationary phase, with 2% aqueous
acetic acid (A) and acetonitrile (B) as mobile phases. Separation
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was performed using the HPLC method described by De
Beer et al. (2012). The column temperature was controlled
at 30◦C. A flow rate of 1 mL/min was used with the
following mobile phase gradient: 0–2 (8% B), 2–27 (8–
38% B), 27–28 (38–50% B), 28–29 (50% B), 29–30 (50–
8% B), and 30–40 min (8% B). The dihydrochalcones [PDG
and 3-hydroxyphloretin-3′,5′-di-C-hexoside (HDH)], flavanones
(eriocitrin and hesperidin), benzophenones (IMG and IDG), and
benzoic acid (protocatechuic acid) were quantified at 288 nm,
whereas the xanthones (mangiferin and isomangiferin), flavones
(vicenin-2, scolymoside, and luteolin), and hydroxycinnamic acid
(p-coumaric acid) were quantified at 320 nm.
A 7-point calibration curve was set up for all the available
standards. Due to the unavailability of a reference standard, HDH
were expressed in terms of PDG equivalents.
LA7 Cell Culture and Mammary Tumor
Induction
The rat mammary gland tumor cell line, LA7 (ATCC No
CRL2283) was obtained from the American Type Culture
Collection (ATCC, Manassas, VA, United States). LA7 cells were
cultured in high glucose (4.5 g/L) Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10% FCS, 100 IU/mL
penicillin, and 100 µg/mL streptomycin (1% penicillin–
streptomycin) (Sigma-Aldrich, South Africa) and maintained
at 37◦C in a humidified atmosphere of 5% CO2. Stock cultures
of LA7 cells at Passage number (P#) 12 were seeded in 75 cm2
flasks (SPL Life Sciences) and allowed to multiply for 48 h.
Thereafter, cells (P#13) were transferred into 175 cm2 flasks
(Nest Biotechnology) at 80–90% confluency and maintained
in high glucose DMEM supplemented with 10% FCS and
1% penicillin–streptomycin for 72–96 h. To harvest cells,
trypsin-EDTA was added to detach cells and neutralized using
phosphate-buffered saline (PBS; Sigma-Aldrich). Cells were
immediately centrifuged at 100 × g for 10 min at 4◦C. For
viability detection, the cells were stained with trypan blue and
counted using a cell counter.
For tumor induction, LA7 cells (prepared as described above)
at P#14 were re-suspended at a concentration of 18 × 106
in 300 µL of PBS per rat and inoculated subcutaneously
into the mammary fat pad (right flank) using a tuberculin
syringe and 26G needle. Injection of cells was performed under
isoflurane anesthesia and cells (P#14) were used within 70 min of
preparation.
Animals and Experimental Design
This study was carried out in accordance with the
recommendations of the South African National Standards
10386: 2008, Research Ethics Committee: Animal Care and Use
of Stellenbosch University. The protocol was approved by the
Research Ethics Committee: Animal Care and Use of Stellenbosch
University (Ethical Approval No: SU-ACUM14-00019).
Female Sprague-Dawley (SD) rats (180 ± 20 g, 49 days of
age) were obtained from the Animal Facility of Stellenbosch
University, South Africa. The animals were housed in propylene
cages under standard conditions (temperature 22◦C, relative
humidity 40%, 12 h light–dark cycle). Animals were acclimatized
for 1–3 weeks before the commencement of experimental
procedures. Standard rodent pellets and tap water were accessible
ad libitum to the animals. Rats were randomly divided into 13
groups as indicated below and summarized in Figure 1.
A mixture of ethanol and castor oil (ethanol:castor oil;
1:9) served as vehicle control. SM6Met, 17β-estradiol (E2),
and SOC endocrine therapies (TAM, FUL, and LET) were
dissolved/suspended in ethanol and diluted 10-fold with castor
oil [1:9; 3 mL/kg body weight (BW)]. The doses of SM6Met
(Visser et al., 2013, 2016), E2 (Kerdelhue and Jolette, 2002),
TAM (Shamsabadi et al., 2013; Bakar et al., 2017), FUL (Osborne
et al., 1995; Bean et al., 2015), and LET (Sinha et al., 1998)
are similar to those previously published. All treatments were
administered by oral gavage. Normal healthy rats in group 1 were
treated daily with vehicle (CV) throughout the 28 days study
duration. Groups 2 and 3 consisted of tumor-bearing rats treated
daily with water (TW) or vehicle (TV), respectively, for 2 weeks
prior to tumor induction and continued for 2 weeks thereafter.
Groups 4–7 were pre-treated with increasing SM6Met (S) doses
(100, 200, 300, and 500 mg/kg BW/day) for 2 weeks prior
to tumor induction and treatment was continued for 2 weeks
thereafter. Animals in groups 8, 9, and 10 were pre-treated with
vehicle for 2 weeks before mammary tumor induction, after
which treatment was switched to SOC endocrine therapies, TAM
and LET (10 mg/kg BW/day), and FUL (5 mg/kg BW/week),
respectively, and continued for 2 weeks. Animals in groups
11 and 12 were also initially treated with vehicle for 2 weeks
prior to tumor induction and treatment was switched to E2 at
100 µg/kg BW/day (E2S100) and 1000 µg/kg BW/day (E2S1000),
respectively, after tumor induction. Lastly, animals in group 13
(E2L1000) were pre-treated with 1000 µg/kg BW/day of E2 for
2 weeks prior to exposure to tumor cells and treatment was
continued for 2 weeks afterward. Number of rats per group,
n = 10 for all treatment groups except TAM (n = 15) and E2S1000
(n = 5).
Tumor Measurement
Palpation of mammary tumors began 2 days post mammary
tumor induction. BW was also monitored daily after
development of measurable tumors. For tumor volume
estimation, the longest and shortest diameters of the tumor were
measured in all rats with a digital caliper.
Tumor volume was calculated using the formula:
length × width2/2, as previously described by Ciomei et al.
(2007).
At the end of the treatment period, rats were euthanized
under anesthesia by cardiac puncture with a sterile syringe.
Blood samples were collected in Z-serum clot activator tubes
and centrifuged at 3500 rpm (10 min) for serum separation.
Serum samples were stored at −20◦C for biochemical analysis.
Mammary tumors were excised and weighed. The liver,
kidneys, spleen, and heart were collected, weighed, snap frozen
in liquid nitrogen, and stored at −20◦C. For histological
evaluation, sections of liver and kidney tissues were preserved
in 10% neutral-buffered formalin solution. Five micrometers of
thick sections of paraffin-embedded tissues were stained with
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FIGURE 1 | Experimental protocol. Animals were assigned into 13 different groups (groups 1–13). Treatment commenced 2 weeks prior to tumor induction on
day-14. Tumor induction with LA7 cells occurred on day 0 ( ) for all groups except group 1, which received a PBS injection ( ). The treatment continued up to
day 14 (red vertical line denotes end of treatment) and animals were euthanized on day 15. See text for further details.
hematoxylin and eosin (H&E) and slides were examined under
a light microscope.
Measurements of Biochemical
Parameters
Biomarkers for organ function [alkaline phosphatase (ALP),
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), creatinine, urea, and albumin] and lipid profile
(total cholesterol, HDL-cholesterol, and triglycerides) were
determined in the serum using kits from Horiba ABX Pentra
(Montpellier, France) and analyzed on Horiba ABX Pentra 400
analyzer (Horiba ABX, France) according to the manufacturer’s
guidelines.
Cell Lysate Preparation and Western Blot
Analysis
Rat mammary tumor LA7 cells and monkey kidney fibroblast
COS-1 cells obtained from ATCC, United States, were cultured
in high glucose (DMEM supplemented with 10% FCS and
1% penicillin–streptomycin). The human MCF-7 BUS BC cell
line (a kind gift from A. Soto, Tufts University, Boston,
MA, United States) was cultured in high glucose DMEM
supplemented with 5% (v/v) heat-inactivated (HI)-FCS (Sigma-
Aldrich, South Africa) and 1% penicillin–streptomycin.
The cells were seeded at a density of 2.5 × 105 cells into
6-well tissue culture plates and allowed to grow to 80–90%
confluency. For cell lysis, 400 µL/well of lysis/loading buffer
(40 mM Tris–HCl, pH 6.8, 2% β-mercaptoethanol, 8% glycerol,
2% SDS, and 0.04% bromophenol blue) was added. Cells were
scraped and transferred to sterile microcentrifuge tubes and
boiled at 96◦C for 10 min. The cell lysates were resolved using
a 10% SDS–PAGE gel and transferred onto a nitrocellulose
membrane (Bio-Rad Laboratories, Inc.). The blots were blocked
in Tris Buffer Solution-Tween 20 (TBS-T) containing 10%
non-fat powdered milk for 90 min at room temperature. For
immunodetection, the blots were probed with primary antibodies
specific for ERα (HC-20; 1:1000; Santa Cruz Biotechnology),
ERβ (ab3576; 1:1000, Abcam), and GAPDH (FL-335;1:3000;
Santa Cruz Biotechnology) overnight at 4◦C and subsequently
incubated with goat anti-rabbit IgG horseradish peroxidase
conjugated secondary antibody (SC-2030; 1:1000; Santa Cruz
Biotechnology) for 90 min at room temperature. The proteins
were visualized with the ECL enhanced chemiluminescence
detection kit (Bio-Rad Laboratories, Inc.) and bands were
scanned and quantified with the myECL imaging system
(ThermoScientific, United States).
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Statistical Analysis
The data from the rat study were expressed as either mean± SEM
or median± interquartile range (IQR). The commercial software
program, GraphPad Prism Version 5 (GraphPad Software Inc.,
San Diego, CA, United States) was used for statistical analyses
and graphs. One-way analysis of variance (ANOVA), followed by
Dunnett’s post hoc test was used to test for significant differences
at P < 0.05 between the groups.
RESULTS
Phenolic Composition of SM6Met
The major phenolic compounds present in SM6Met were
quantified using HPLC-DAD analysis (Table 1). The compounds
were from diverse phenolic sub-groups such as: flavones
(vicenin-2, scolymoside, and luteolin), flavanones (hesperidin
and eriocitrin), xanthones (mangiferin and isomangiferin),
dihydrochalcones (PDG and HDH), benzophenones (IMG and
IDG), and phenolic acids (protocatechuic acid and p-coumaric
acid). The newly prepared extract of SM6Met, used in the current
study, contained all the compounds quantified in previously
prepared SM6Met extracts at comparable concentrations, except
for luteolin, which was present at a lower concentration than in
previous extracts, and IMG and protocatechuic acid, which were
present at higher concentrations than in previous extracts (Visser
et al., 2013; Mortimer et al., 2015).
The Decrease in the Growth of
LA7-Induced Mammary Tumors Caused
by SM6Met Is Comparable to That of the
SOC, Tamoxifen
To investigate the effects of treatments on tumor growth in a
rat model of mammary gland tumorigenesis, LA7 cancer cells
TABLE 1 | Major polyphenols present in newly prepared Cyclopia subternata
extract, SM6Met, as analyzed by HPLC-DAD.
Compound Content
(g/100 g SM6Met)
Scolymoside 2.844
Hesperidin 1.881
Mangiferin 1.844
3′,5′-Di-β-D-glucopyranosylphloretin (PDG) 1.776
3-Hydroxyphloretin-3′,5′-di-C-hexoside (HDH)∗ 1.370
3-β-D-Glucopyranosyl-4-β-
D-glucopyranosyloxyiriflophenone (IDG) 0.999
Eriocitrin 0.820
3-β-D-Glucopyranosyliriflophenone (IMG) 0.775
Isomangiferin 0.553
Vicenin-2 0.187
Protocatechuic acid 0.154
Luteolin 0.023
p-Coumaric acid co-elution
∗Quantified in PDG equivalents.
(18× 106) were injected orthotopically into the mammary fat pad
of female Sprague-Dawley rats for tumor induction. Although
most of the rats developed palpable tumors as early as 48 h after
injection of cells, measurable tumors were only developed in all
the rats from day 4. Tumor incidence was one in all cases and
thus only tumor volume and weight were compared. Tumors
in the vehicle (TV) and water (TW)-treated groups showed
a rapid growth progression from day 4 with a peak volume
observed on day 10 (Figure 2 and Supplementary Figure S1).
Tumor volumes in vehicle- and water-treated groups were not
statistically different, which shows that the vehicle did not
significantly impact tumor growth. From day 11, tumor volume
declined in these rats independent of treatment and by day 14,
tumor volumes had declined considerably in the two control
groups.
Daily oral administration of the well-characterized
phytoestrogenic extract, SM6Met (Table 1) at four doses
(100, 200, 300, and 500 mg/kg BW) for 28 days, starting 14 days
prior to tumor induction, substantially reduced tumor volume
relative to TV at all doses (Figure 2A). Specifically, the full-time
course of tumor volume for all four SM6Met concentrations was
significantly (P < 0.001) reduced compared to control (TV).
Of the SOC therapies investigated, TAM (10 mg/kg BW),
a SERM, significantly (P < 0.01) decreased tumor volume
progression and a substantial reduction in tumor volume was
observed until day 14. Interestingly, TAM is the only SOC
endocrine therapy that has previously been investigated on LA7-
induced tumor growth and the inhibitory effect of TAM observed
in the current study is in line with results of previous investigators
(Shamsabadi et al., 2013; Karimian et al., 2015). This is the first
study to report on the effects of the SOC therapies, FUL and LET,
on LA7 mammary tumorigenesis (Figure 2B and Supplementary
Figure S2). We did not observe a substantial effect on the time
course of tumor volume progression after treatment with FUL,
although a significant reduction (P < 0.01) in tumor growth on
day 6 was recorded. In contrast, treatment of tumor-bearing rats
with LET significantly (P < 0.05) reduced tumor growth from
days 4–10 in comparison to TV, however, the effect was not as
pronounced as for TAM.
Treatment with E2S100 and E2S1000 significantly (P < 0.05)
suppressed tumor growth but only up to day 8. Furthermore, as
shown in Figure 2C, statistical analysis of the full time course
up to 14 days indicates that both the E2S100 and the E2S1000
groups are statistically different from the control group (TV).
Moreover, in the E2L1000-treated rats, tumor volume increased
substantially in comparison to TV (Figure 2C), although the
increase in tumor volume was only significant (P < 0.05) from
day 12 post tumor induction (after 26 days of E2 treatment).
The time course of percentage tumor inhibition
(Supplementary Figure S2D) indicates that at the highest
concentration (S500), the effect of SM6Met is not statistically
different from the SOC, TAM, but does differ significantly from
FUL (P < 0.001) and LET (P < 0.05). Specifically, the tumor-
suppressing effect of SM6Met at the highest dose was comparable
to that of TAM on day 4 post tumor induction (SM6Met; 56.1%,
vs. TAM; 40.0%), day 6 (SM6Met; 70.30%, vs. TAM; 52.5%),
day 8 (SM6Met; 44.3%, vs. TAM; 48.8%), and day 10 (SM6Met;
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FIGURE 2 | Time course of mammary tumor volume progression in treated rats. (A) SM6Met (S) at varying doses, (B) SOC therapies, and (C) E2. Points are
indicative of average value of tumor volume ± SEM. Statistical analysis was performed using repeated measures ANOVA plus Dunnett’s post hoc test comparing the
mean tumor volume time courses of treatments to vehicle-treated tumor control (TV). Tests were considered statistically significant at P < 0.05 (∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001). See text for further details.
47.5%, vs. TAM; 48.9%). However, it should be noted that while
SM6Met was introduced 14 days prior to tumor induction, TAM
treatment only commenced after tumor induction.
Effect of Treatments on Tumor Growth on
Day 10 and Day 14 Post Tumor Induction
Although progressive tumor growth was observed in the tumor
control (TV) group from day 4 to day 10, an initial decline in
tumor volume was noted after day 10 in the TV control group,
which continued to day 14 (Figure 2). Thus, a comparison at
these 2 days seems warranted and Figure 3 represents the effects
of treatments on median tumor volume on day 10 and day 14 post
tumor induction.
Although SM6Met significantly delayed tumor growth in rats
compared to TV (Figure 2A), this effect was not observed beyond
day 10. Thus while median tumor volume was significantly
(P < 0.05) reduced in the SM6Met treatment groups on day
10, the decrease was not significant on day 14 (Figures 3A,D).
However, rats treated with SM6Met still had a reduced median
tumor volume on day 14 post tumor induction compared to
TV control. Specifically, a reduction of 23.2, 24, 37, and 37%,
respectively, for the S100, S200, S300, and S500 groups, was
observed, while a 47% inhibition was observed with TAM.
A direct statistical comparison between all the SM6Met groups
and TAM on day 14 also indicates no significant difference.
In terms of the SOC therapies, interestingly, by the end of the
treatment period (day 14), a significant reduction (P < 0.01) in
median tumor volume was only sustained in TAM-treated rats
in comparison to the TV group (Figures 3B,E). Although LET
significantly (P< 0.01) suppressed median tumor volume on day
10 (Figure 3B), no significant suppression was observed on day
14 in groups treated with LET and FUL (Figures 3B,E).
The protective effect of E2 in the E2S100 and E2S1000
treatment groups was not observed on day 10 and day 14
(Figures 3C,F). However, exposure of rats to E2 before LA7 cell
injection in the E2L1000 group significantly increased median
tumor volume in rats on day 14 (P < 0.05), but not on day 10.
These results suggest the influence of treatment duration and
dose in the dual role of estrogen as a protector or a promoter of
tumor growth.
Effect of Treatments on Tumor Mass on
Day of Euthanisia
At necropsy (day 15 post tumor induction), no significant
difference was observed in tumor weight in all treatment
groups in comparison to vehicle-treated tumor-bearing
animals (Figures 4A–C). This may be explained by the
continuous and considerable decline in tumor volume in vehicle-
treated TV starting from the 10th day post tumor induction
(Figure 2).
Effect of Treatments on Body Weight and
Selected Organ Weights in LA7-Induced
Tumorigenic Rats
As shown in Table 2, BW gain was found to be significantly
lower (P < 0.05) in the TV group in comparison to non-
tumorigenic rats treated with vehicle (CV). Furthermore, no
significant difference was observed between TW and TV groups
(Table 2), which indicates that it is rather the induction of the
tumor and not use of vehicle that caused a significant reduction
in BW in the TV group. No significant difference in BW gain
was observed in rats administered SM6Met and SOC endocrine
drugs (TAM, FUL, LET) in comparison to TV rats. However,
significantly lower BW gain was observed in the S500 (P< 0.001)
and TAM-treated rats (P < 0.001) relative to the CV group.
Additionally, rats in the E2L1000 treatment group, but not the
E2S1000 or E2S100 groups, had significantly (P < 0.05) lower
BW gain compared to the TV group. Furthermore, BW in both
the E2L1000 and E2S1000 groups differed significantly (P< 0.01)
from the CV group.
No significant alteration was observed in relative organ
weights (%) after SM6Met and TAM treatment, when compared
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FIGURE 3 | Effects of treatments on mammary median tumor volume on the 10th day (A–C) and 14th day (D–F) post tumor induction. (A,D) SM6Met, (B,E) SOC
endocrine therapies, and (C, F) E2. Data are presented as median tumor volume with interquartile ranges (IQR). Statistical analysis was performed using one-way
ANOVA plus Dunnett’s post hoc test comparing all treatments to vehicle-treated tumor control (TV). Tests were considered statistically significant at P < 0.05
(∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001).
FIGURE 4 | Effects of treatments on tumor mass (g) in rats on day of euthanasia. (A) SM6Met, (B) SOC endocrine therapies, and (C) E2. Data are presented as
median ± IQR. Statistical analysis was performed using one-way ANOVA plus Dunnett’s post hoc test comparing tumor mass of treatments to vehicle-treated tumor
control (TV). Tests were considered statistically significant at P < 0.05.
to TV and CV groups, except for a significant elevation
(P < 0.05) in relative spleen weight (%) in the S200 group in
comparison to CV group. Furthermore, LET did not significantly
affect organ weights in comparison to TV, but did significantly
(P < 0.001) reduce kidney weight in comparison to the CV
group. FUL significantly (P < 0.05) reduced liver weight in
rats, but did not alter the weight of the kidney, heart, and
spleen, in comparison to TV treatment group. Treatments with
FUL, however, significantly (P < 0.05) reduced kidney weights
when compared to the CV group. No significant alteration was
observed in organ weights in the two E2S treatment groups
(E2S100 and E2S1000). A significant (P < 0.001) increase in liver
and a significant (P < 0.01) decrease in spleen weights in the
E2L1000 treatment group relative to TV were observed, even
though no marked effect of treatment was observed on the %
relative weights of kidney and heart.
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TABLE 2 | Effect of treatments on BW and selected organ weights.
BW gain (g) % Relative organ weight
Liver Kidney Heart Spleen
CV 53.90 ± 3.03 3.79 ± 0.07 0.73 ± 0.01 0.38 ± 0.01 0.21 ± 0.01
TV 38.74 ± 3.51b∗ 3.82 ± 0.11 0.69 ± 0.01 0.38 ± 0.01 0.23 ± 0.01
TW 46.83 ± 5.80 3.43 ± 0.03a∗ 0.70 ± 0.02 0.36 ± 0.01 0.24 ± 0.01
S100 47.91 ± 4.95 3.74 ± 0.08 0.71 ± 0.02 0.38 ± 0.00 0.23 ± 0.01
S200 50.21 ± 4.61 3.62 ± 0.08 0.69 ± 0.02 0.37 ± 0.01 0.24 ± 0.01b∗
S300 45.76 ± 4.87 3.81 ± 0.06 0.72 ± 0.01 0.37 ± 0.01 0.24 ± 0.01
S500 29.50 ± 1.95b∗∗∗ 3.52 ± 0.05 0.71 ± 0.01 0.38 ± 0.01 0.22 ± 0.01
TAM 31.10 ± 2.00b∗∗∗ 3.79 ± 0.10 0.74 ± 0.01 0.39 ± 0.01 0.23 ± 0.01
FUL 44.22 ± 4.73 3.47 ± 0.07a∗ 0.70 ± 0.01b∗ 0.38 ± 0.01 0.22 ± 0.01
LET 52.19 ± 2.86 3.59 ± 0.06 0.65 ± 0.01b∗∗ 0.37 ± 0.01 0.23 ± 0.01
E2S100 48.71 ± 3.39 3.63 ± 0.09 0.71 ± 0.01 0.38 ± 0.01 0.23 ± 0.01
E2S1000 28.52 ± 3.61b∗∗ 4.03 ± 0.11 0.72 ± 0.01 0.36 ± 0.01 0.19 ± 0.01
E2L1000 22.81 ± 1.94a∗,b∗∗ 4.52 ± 0.06a∗∗∗,b∗∗∗ 0.71 ± 0.01 0.36 ± 0.01 0.19 ± 0.00a∗∗
Data are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA plus Dunnett’s post hoc test. Tests were considered statistically significant
at P < 0.05 (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001). aValues differ significantly from those of vehicle-treated tumor control (TV). bValues differ significantly from vehicle-
treated normal control (CV). % Relative organ weight = (organ weight (g) on day of sacrifice)/(BW (g) on day of sacrifice) × 100.
Effect of Treatments on Serum
Biomarkers and Histological Changes of
Organ Function and Lipid Profile
Table 3 represents the effects of the phytoestrogenic extract,
SM6Met, E2, and the SOC endocrine drugs on biochemical
parameters in rats. The increase in liver mass seen in TV
group in comparison to TW, possibly due to castor oil, was
not accompanied by a significant decrease in BW (Table 2)
nor a significant increase in the levels of liver damage markers
(Table 3), thus we regard the effect of vehicle treatment a non-
adverse effect (Hall et al., 2012). Previous work (Irwin, 1992) that
has shown that castor oil significantly increases liver weights and
ALP levels also came to the same conclusion and ascribed the
changes to increased metabolic activity rather than toxicity. As
observed in the TV group, tumor induction caused a significant
elevation of ALP (P < 0.01) in comparison to the CV group,
whereas other serum markers of liver injury (ALT and AST) were
unchanged. Liver injury in the TV group is supported by liver
sections showing necrosis (Figure 5). Furthermore, no significant
differences were observed in the levels of serum albumin, a
marker of both liver and kidney damage (Clark and Kruse,
1990), lipid profile (total cholesterol, HDL-cholesterol, and
triglycerides), and kidney function markers (urea and creatinine)
in the TV group in comparison to the CV group. Micrographs
of kidney sections showed normal structure for the TV group
(Figure 6).
SM6Met was non-toxic to the rats at all doses, as no significant
alteration in the levels of the serum liver enzymes (ALT, AST,
and ALP) was observed compared to TV. Furthermore, SM6Met
did not significantly affect serum levels of albumin, urea, or
creatinine. On the other hand, the result of our study showed
a direct toxic effect of tumor induction (in TV group) and
treatments (TAM, LET; dissolved in vehicle) on liver function
evident by significant alterations in serum markers of liver injury,
whereas these effects were not observed with SM6Met treatments.
The histological effects observed with SM6Met in the liver, as
not accompanied by significant alterations in enzyme markers
in comparison to TV could therefore be due to vehicle’s effect
or provoked by tumor induction. In addition, lipid profiles of
tumorigenic rats treated with SM6Met did not differ from the TV
or CV group.
Whereas no significant change was observed in all investigated
biomarkers following FUL treatment, alteration in liver function
markers was observed with the other SOC endocrine treatments,
TAM and LET. Specifically, TAM significantly elevated serum
ALP concentrations (P < 0.001), while LET increased AST
and ALT levels in comparison to TV (Table 3). Lipid profile
and serum levels of urea, creatinine, and albumin did not
differ in all groups treated with the SOC endocrine drugs
compared to TV. However, TAM significantly increased urea
levels relative to the CV group. These results are supported
by the kidney micrographs (Figure 6) showing kidney damage
by TAM.
E2 treatment altered the serum lipid profile. In the E2S1000
and E2L1000 groups, the levels of total cholesterol and HDL-
cholesterol were significantly (P < 0.001) reduced, while
triglyceride levels were significantly (P < 0.001) elevated
compared to the TV group. A significant (P < 0.01) reduction
in the serum levels of HDL-cholesterol was also noticed in the
E2S100 group, whereas levels of total cholesterol and triglycerides
were not significantly altered in this group.
An extended treatment with E2 (E2L1000 group) markedly
elevated (P < 0.001) serum ALT concentrations compared to
TV, but no significant changes were observed with ALP and AST
concentrations. Markers of liver injury were not elevated in the
E2S groups, although a significant decrease in ALP and ALT levels
were observed in E2S1000 (P < 0.01) and E2S100 (P < 0.05)
groups, relative to the TV and CV groups, respectively.
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FIGURE 5 | Light micrographs of liver sections stained with
hematoxylin–eosin (HE; 400×). (A) CV group depicts slightly enlarged
hepatocytes, vesicular nuclei (white arrows), and slightly compressed sinuses
(S); (B) TV group shows slightly enlarged hepatocytes, vesicular nuclei (white
arrows), pyknotic nucleus (black arrows), and single cell necrosis (black arrow
heads); (C) TW group shows vesicular nuclei (white arrows), pyknotic nucleus
(black arrows), dilated hepatic sinusoids (S); (D) SM100 group shows normal
liver architecture; (E) SM200 group shows dilated sinusoids (S); (F) SM300
group shows enlarged hepatocytes; (G) SM500 group shows pyknotic
nucleus (black arrows) and enlarged hepatocytes; (H) TAM group shows
focus of lymphocyte infiltrate with loss of cellular details (white arrow head),
pyknotic nuclei (black arrows), and single cell necrosis (black arrow head);
(I) FUL group shows normal liver architecture; (J) LET group shows enlarged
hepatocyte, dilated sinusoids (S) with lymphocyte infiltrate (white arrow head);
(K,L) E2S (100 and 1000 µg/kg/day, respectively) groups showing normal
liver architecture and slightly enlarged hepatocytes; (M) E2L1000 group
reveals hepatocyte degeneration and necrosis (black arrow heads).
Albumin levels were significantly elevated in E2L1000 group,
but not the E2S1000 group, while creatinine and urea levels
were not significantly affected in either group. The only clinical
situation that causes an elevation in serum albumin is acute
dehydration (Clark and Kruse, 1990). However, treatment with a
lower dose of E2 (E2S100 group) significantly reduced (P < 0.01)
serum urea levels. Furthermore, kidney sections (Figures 6K–M)
suggest normal structure.
Expression of Estrogen Receptor (ER)
Subtypes in LA7 Cells
Estrogen receptor expression is an important prognostic factor
for BC and is vital for endocrine treatment recommendation.
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FIGURE 6 | Representative histological photomicrographs of kidney sections
stained with hematoxylin–eosin (HE; 400×). (A) CV; (B) TV; (C) TW; (D–G)
SM6Met (100, 200, 300, and 500 mg/kg/day, respectively); (I) FUL; (J) LET;
(K,L) E2S (100 and 1000 µg/kg/day, respectively); (M) E2L1000 showing
normal structure of renal glomeruli and (H) TAM showing shrunken glomeruli.
Thus, an investigation of the ER expression levels in LA7 cells is
relevant to the current study. As a control, the expression of ERα
and ERβ in the human BC cell line, MCF-7 (high ERα/ERβ ratio),
and ER-negative monkey kidney fibroblast COS-1 cells were
examined in the present study. As expected, ERα was more highly
expressed than ERβ in MCF-7 cells, while no ER expression was
detected in COS-1 cells (Figure 7). In contrast, ERα expression
was weakly detected in LA7 cells, while ERβ was more highly
expressed. The expression of both ER subtypes (ERα and ERβ)
appears to decrease with increasing passaging of the LA7 cells.
LA7 cells at passage number 14 (P#14), used for tumor induction
in the present study, expressed a low ERα/ERβ ratio, which is
indicative of higher ERβ levels compared to ERα levels.
DISCUSSION
Extended exposure to high levels of endogenous hormones,
primarily estrogen, due to early menarche, late menopause,
exogenous estrogen replacement therapy, prolonged oral
contraceptive use, obesity, among others, is strongly associated
with increased risk of BC (Travis and Key, 2003; Dall and Britt,
2017). The tumor promoting effects of E2 (Li et al., 2002; Singh
et al., 2011) and synthetic estrogens (Palmer et al., 2002; Ueda
et al., 2002; Singh et al., 2011) are also well documented in animal
models of mammary carcinogenesis. Data from the current
study, however, revealed that administration of E2 at 100 µg/kg
BW/day (E2S100) and 1000 µg/kg BW/day (E2S1000) for
2 weeks significantly (P < 0.05) suppressed tumor progression
(Figure 2C) in comparison to vehicle-treated controls, at least
in the first 10 days post mammary tumor induction. In contrast,
the higher dose of E2 (E2L1000) administered for a prolonged
period (4 weeks) starting before tumor induction, significantly
(P < 0.05) stimulated tumor progression at a later stage (26 days,
i.e., 12 days post tumor induction). Although the observed tumor
suppressive effect of estrogen in the current study contrasts with
evidence supporting the tumor promoting effects of estrogen,
this may be explained in part by the administered estrogen dose
and treatment duration.
Although numerous studies have emphasized the primary role
of estrogen in increasing BC risk, the inhibitory role of E2 (20 µg)
injected concomitantly with 4 mg progesterone on mammary
cancer over a 40-day period has been reported (Grubbs et al.,
1983). In addition, a sustained treatment with 20 µg E2 in silastic
capsules for 1 week was effective in decreasing the multiplicity
and increasing the latency of mammary tumorigenesis induced
by MNU in rats (Rajkumar et al., 2001). Treatment with high
dose estriol (30 mg, 200 µg) or ethinyl estradiol (100 µg),
singly or in combination with progesterone for 1 or 3 weeks,
also reduced mammary tumor incidence and multiplicity in
a chemical carcinogen rat mammary model (Rajkumar et al.,
2004). Furthermore, Rajkumar et al. (2007) demonstrated a
protective effect of pregnancy estrogen levels against mammary
tumorigenesis attained by a sustained exposure to 100 µg of
E2, either alone or combined with progesterone, for 2 weeks
in genetically engineered mouse models. Experimental evidence
also exists for the protective action of short-term treatment
(3 weeks or less) with physiological levels of E2 and progesterone
against mammary carcinogenesis (Sivaraman et al., 1998;
Guzman et al., 1999). Although the exact mechanisms involved
in protection of BC by E2 are unknown, reductions in the
proliferative potential of the mammary cells or hormone-induced
changes at the mammary stroma or systemic level are some
suggested mechanisms (Rajkumar et al., 2007). As macrophage
infiltration and increased expression of inflammatory cytokines
in the mammary tissues are characteristics of LA7-induced
mammary tumors (Bakar et al., 2017), the immunomodulatory
effect of exogenously administered estrogen (Attanasio et al.,
2002; Lang, 2004) could also contribute to the delay in the tumor
progression in this model. Nonetheless, our study is the first to
report on the effect of E2 on tumor growth induced by LA7 cells.
The E2 dose (100 µg/kg BW/day or 1000 µg/kg BW/day)
used in our study may be considered physiologically relevant.
Administration of 100 µg, 200 µg, or 30 mg of E2 in
silastic capsules in a previous study resulted in physiologically
relevant E2 levels of 67, 94, and 143 pg/mL, respectively. These
concentrations reflect the levels of serum E2 (55–630 pg/mL) in
pregnant Long Evans and Sprague-Dawley rats (de Lauzon et al.,
1974; Watson et al., 1975; Rajkumar et al., 2001). Furthermore,
serum E2 levels corresponding to the mid-menstrual cycle in
pre-menopausal women are between 100 and 400 pg/mL (Kratz
et al., 2004). Although the oral route (hence first pass through
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FIGURE 7 | ER subtype expression in LA7 cells. A representative western blot is shown displaying the ER (ERα and ERβ) status of the rat mammary cell line (LA7),
human BC cell line (MCF-7), and monkey kidney fibroblast (COS-1) cells. Quantification of the ER subtypes was done using the myECL Imaging software and is
presented in figures below western blot.
the liver) of E2 administration in the present study, in addition
to the influence of ovarian estrogen production, might result in
differential E2 pharmacokinetics.
The data showed that treatment with SM6Met significantly
delayed mammary tumor growth at all doses demonstrating its
chemopreventative effect. The autoregressive nature of the tumor
is observed in all the tested groups, including the TV group,
and thus seems to be a property of the tumor model rather
than the treatment. The inference on the chemopreventive effect
of SM6Met was therefore based on the positive outcome of
SM6Met treatment in retarding tumor growth in the first 10 days.
Although this effect was not as profound after day 10, this does
not invalidate the effect observed till day 10. Furthermore, as
LA7 tumors contain a heterogeneous population of cells, ranging
from stem cells to fully differentiated cells, that have proliferative
capabilities that range from highly to limited proliferative
capacity (Zucchi et al., 2007, 2008), the autoregression of the
tumor observed after day 10 may be due to differentiation of the
LA7 cells and thus it would appear that SM6Met treatment targets
the highly proliferative undifferentiated cells in the tumor.
Although no obvious dose response was noticed with SM6Met
treatment, the chemopreventative effect of SM6Met at the highest
dose (500 mg/kg BW/day) was significantly higher (P < 0.01)
than at the lowest dose (100 mg/kg BW/day) and was comparable
to that of TAM. However, it should be noted that TAM, like
other SOC’s (LET and FUL), was only administered after tumor
induction to improve tolerability and minimize side effects. The
hepatotoxic effect of TAM at a dose of 6 mg/kg administered
over 2 weeks has been demonstrated in rats (Gao et al., 2016).
The use of LET and FUL have been solely approved for BC
treatment, while TAM is also widely use in treatment due to
its limiting side effect profile as a chemopreventive agent. In
contrast, administration of SM6Met prior to tumor induction
was considered a more rational option in the present study
as the leaves of the C. subternata from which SM6Met was
extracted is used to produce a honey-flavored herbal infusion,
widely consumed as honeybush tea in South Africa. Furthermore,
since this is the first study to assess the potential toxic effect of
SM6Met, a longer-term safety and tolerability assessment was
considered warranted. Moreover, prevention of BC presumes
prior administration of the drug or extract as evidenced in both
animal (Hollingsworth et al., 1998; Wang and Zhang, 2017) and
in clinical (Kinsinger et al., 2002) chemopreventative studies.
However, as the LA7 model is an orthotopic method of tumor
development, in terms of chemoprevention, it does not evaluate
effects on cancer initiation or promotion. Furthermore, the
current study, which focusses on secondary prevention (De Flora
et al., 2001), cannot distinguish between the chemopreventative
effects of SM6Met on tumor establishment and progression.
The inhibitory action of SM6Met on BC cell proliferation and
cell cycle progression has been reported previously (Visser et al.,
2013). More recently, in an MNU model of BC, rats fed a SM6Met
formulated diet (containing 2500 ppm of the SM6Met aimed at
an exposure of 200 mg/kg BW) for 140 days showed a significant
reduction in tumor volume (53%) (Visser et al., 2016). In the
present model of LA7-induced tumorigenesis, SM6Met treatment
at an equivalent dose of 200 mg/kg BW (S200), but administered
for only 26 days, reduced tumor volume by 33%, while a 48%
reduction in tumor volume was observed at the highest dose
(S500).
The chemopreventive effects of SM6Met may be attributable
to the active compounds in the extract (Table 1). Some
major phenolic compounds identified in SM6Met, particularly
hesperidin (a flavanone) and mangiferin (a xanthone), have
Frontiers in Pharmacology | www.frontiersin.org 12 June 2018 | Volume 9 | Article 650
fphar-09-00650 June 18, 2018 Time: 16:8 # 13
Oyenihi et al. Mammary Tumor Chemoprevention by SM6Met
demonstrated anti-cancer effects in vitro (Lee et al., 2010;
Cuccioloni et al., 2016). Specifically, mangiferin, the major
xanthone in SM6Met, has demonstrated broad-spectrum efficacy
against an array of different cancers in vitro and in vivo with
an antitumor efficacy comparable to that of the anticancer drug,
cisplatin (Gold-Smith et al., 2016). The structural requirements
for the inhibitory effect of flavones on aromatase are attributed
to the position of the 4′-hydroxyphenol group, which increases
binding affinity to the aromatase enzyme (Kao et al., 1998;
Rice and Whitehead, 2006). However, no study has specifically
reported on the effect of scolymoside and vicenin-2 on BC,
although these flavones contain a 4′-hydroxyphenol group and
are thus potentially worthy of investigation for their AI and
tumor-suppressing action. Although the cytotoxic and apoptotic
effects of dihydrochalcones, specifically phloretin, have been
reported in prostate cancer and breast tumor cells (Szliszka et al.,
2010; Kim et al., 2013), to the best of our knowledge, there is
no information on the antitumor effects of phloretin derivatives
such as PDG and HDH, that have been identified in SM6Met
(Table 1). Thus, it is likely that a complex interaction of these
compounds is responsible for the antitumor effect of SM6Met via
diverse mechanisms of action.
Furthermore, previous studies from our laboratory using
BC cell lines have demonstrated the antiproliferative effects
of SM6Met via a mechanism involving the selective ER
subtype modulating (SERSM) action of SM6Met, by specifically
demonstrating that SM6Met acts as an ERβ agonist and an ERα
antagonist (Visser et al., 2013). The mammary tumor suppressive
effects of SM6Met in the present study might thus be due in part,
to its opposing effects on the ER subtypes.
An investigation of the ERα and ERβ expression status could
provide insight into the possible mechanisms of action for
pharmacological regulators of ER activity. In the present study,
ERα, in contrast to ERβ, was weakly expressed in LA7 cells
at all passages examined. However, western blot analysis also
revealed a decrease in the ratio of ERα:ERβ protein expression
with increasing cell passage number, highlighting the possible
role of culturing conditions in receptor protein expression. The
LA7 cells (P#14) used for tumor induction in the present study
appeared to express higher ERα and ERβ protein levels compared
to cells at a latter passage (P#17), which had no detectable ERα.
An opposite ER subtype phenotypic profile (eightfold higher
ERα than ERβ protein expression) was observed in the MCF-
7 ER+ cells. Recently, in the study of Vela and Escrich (2016),
no detectable ERα protein expression was observed in LA7 cells;
however, there was no report on the protein expression status
of ERβ.
Although it is well established that ERα promotes the growth
of breast tumors, the specific functions of ERβ are less well
understood. Experimental evidence exists for the inhibitory role
of ERβ on the proliferative response of ERα in cells where they are
co-expressed. ERβ expression has also been linked to a reduction
in the aggressiveness of breast tumors and improved disease-free
survival rates, compared with ERβ-negative tumors (Hartman
et al., 2006).
The reason for an earlier tumor appearance and earlier
regression in the current study in contrast the available evidence
on growth progression of LA7-tumors (Syam et al., 2016) is
not clear. Tumor progression was reported in the tumor control
group for 4 weeks, while in our study, tumor growth was observed
for only 10 days in the vehicle treated tumor control group
(TV). Furthermore, we also detected measurable tumors as early
as on the 4th day post tumor induction, in contrast to tumor
detection at a later time-point (7–10 days) in this study. One
could argue that the discrepancy between the two studies might
be attributable to the higher number of cells (18 × 106) used
for tumor induction in the present study in comparison to
6 × 106 cells used in the study of Syam et al. (2016). However,
none of the other studies on LA7 tumor model reported tumor
progression, ER subtype phenotype of the LA7 cells, and the
passage number was not mentioned, therefore no comparison can
be made in this regard.
Tamoxifen is the only SOC endocrine therapy that has
previously been investigated in LA7 tumorigenesis. The
observation from the current study of the suppressive effect
of TAM on the growth of LA7 mammary tumorigenesis is in
line with other studies (Shamsabadi et al., 2013; Karimian et al.,
2015). Although the antitumor effect of TAM in the present study
could be mediated via inhibition of ERα activation, the weak
expression of ERα in the LA7 cells used in the current study,
however, suggests the possible involvement of non-ER-mediated
mechanisms of TAM action. Although TAM and its metabolite
4-hydroxy-TAM act by antagonizing the activation of ERα
(Jordan, 2003; Bekele et al., 2016), the beneficial effects of TAM
in BC patients with very low, or no ERα, have also been reported
(Manna and Holz, 2016). Furthermore, numerous in-vitro and
in-vivo BC models have reported on some ER-independent
mechanisms of TAM action (Bogush et al., 2012).
In pre-menopausal hormone-responsive BC, AIs are not
used clinically as a monotherapy because AIs reduce the
negative feedback on the hypothalamic–pituitary–ovarian axis,
further increasing ovarian estrogen production. Estrogen then
competitively antagonizes binding of the inhibitor to the enzyme’s
active site and thus overcomes the effects of AIs on the aromatase
enzyme. The animal model utilized in the current study simulates
pre-menopausal BC due to the presence of ovarian function and
thus it is reasonable to infer that estrogen levels may be higher
in LET-treated rats in comparison to tumor controls. The delay
in mammary tumor growth in LET-treated rats in comparison
to vehicle controls might thus be mediated by elevation of
serum estrogen levels. However, blockade of ovarian estrogen
production has been reported in rats at a high dose (5 mg/kg
BW/day) of LET for 4 weeks (Sinha et al., 1998). On the other
hand, some experimental evidence exists for the beneficial effects
of AIs, like LET (Kubatka et al., 2008a) and anastrozole (Kubatka
et al., 2008b), in a MNU-induced pre-menopausal mammary
carcinogenesis model. Furthermore, Madeira et al. (2013) also
documented a decrease in the proliferation marker, Ki67, in
tumors of patients with much lower ERα than ERβ scores
following treatment with anastrozole, another AI, suggesting a
possible relationship between therapeutic response to AIs and ER
subtype expression.
Data from this study revealed that oral treatment with FUL at
5 mg/kg BW/week did not significantly affect mammary tumor
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growth (Figure 2 and Supplementary Figure S2). Although
FUL has shown a moderate therapeutic effect against triple-
negative BC (ERα−/ERβ+) and inhibition of hormone responsive
(ERα+/ERβ+) BC via upregulation of ERβ mRNA and protein
expression levels (Mishra et al., 2016), the lack of a significant
effect on the time course of tumor growth after cyclic FUL
regimens (oral administration of 5 mg/kg BW/week) in the
present study could be due to the poor oral bioavailability of FUL
(Robertson, 2007). A sustained exposure to FUL via an alternative
route of administration should be considered in future studies.
Induction of mammary tumors in rats caused a drastic
reduction in BW gain (Table 2). Another prominent outcome
of this study is that SM6Met administration did not significantly
affect BW gain in comparison to TV, which may be a possible
reflection of an unaltered nutritional status in SM6Met-treated
rats. No significant changes in BW gain in the TAM group were
observed in comparison to TV, although a decreased weight
gain in comparison to the vehicle-treated normal control (CV)
group was statistically significant (P < 0.001). Furthermore,
no significant alteration in BW gain was observed with any
of the other SOC endocrine therapies (FUL and LET) in
comparison to TV. The inhibitory effect of estradiol on food
intake has been previously established (Blaustein and Wade,
1976; Eckel, 2004). This anorexic effect of estrogen is further
supported by the prevention of weight loss in ovariectomized
animals (Sasayama et al., 2017). A significantly reduced BW
gain observed in the E2L1000 treatment group relative to TV
group in our study could be partly due to this anorexic effect of
E2.
The goal of cancer therapy is to promote cancer cell death,
while minimizing or preventing toxicity to normal cells. No
significant alterations in tissue weight was observed in the
SM6Met-, TAM’-, and LET-treated rats in comparison to the TV
treatment group, although a significant reduction (P < 0.05) in
liver weight was seen with FUL treatment. The liver plays an
important role in the metabolism of estrogens (Mitchel et al.,
1976) and in the current study, a significant (P < 0.001) E2-
induced liver enlargement was observed at the higher dose
and longer treatment duration of E2 (E2L1000), implying
a dose- and time-dependent hepatotoxic action of E2. The
excessive accumulation of estrogen in the liver could interfere
with secretion of other molecules from the liver parenchyma
(Radzikowska et al., 2012), while the increased liver size might
be an indication of drug-induced toxicity as reflected by the data
obtained from analysis of liver injury markers.
The actions of E2 on the immune system are complex
and differ according to its concentration and targeted
functions (Straub, 2007; Khan and Ansar Ahmed, 2016).
Estrogens suppressed spleen weight gain under inflammatory
immunological conditions, but not in naive female mice (Zhou
et al., 2011), suggesting the differential effects of estrogen under
different immunological conditions. Mammary tumors induced
by the orthotopic injection of LA7 cells are linked to increased
activity of inflammatory mediators (Bakar et al., 2017) and thus
in the current study, an elevation (P < 0.01) in relative spleen
weight was noted in rats treated with E2 for a prolonged period
(E2L1000).
Elevated serum concentrations of transaminases (AST and
ALT) and ALP are diagnostic markers for liver injury (Giannini
et al., 2005). It is noteworthy that SM6Met did not significantly
raise the serum concentrations of liver biomarkers in comparison
to the tumor control (TV) group demonstrating the maintenance
of liver integrity in the SM6Met-treated groups. However, data
from this study revealed a differential pattern in the alteration of
serum enzymes in the TV, TAM, LET, and E2 groups suggesting
different mechanisms of liver injury. The pattern of serum
enzyme elevations may indicate the site of liver injury and
distinguish between hepatocellular and cholestatic liver disease
(Murali and Carey, 2014).
Alkaline phosphatase is a membrane-bound enzyme and
is used for the assessment of plasma membrane integrity
(Sharma et al., 2014). It is found on the surface of bile duct
epithelia and may be elevated if bile excretion is inhibited,
resulting in the accumulation of toxic bile acids that cause
cholestatic liver injury (Limdi and Hyde, 2003). Specifically,
in the current study, the preferential increase in serum ALP
concentrations in the LA7-induced tumorigenic control rats
(TV), which was significantly aggravated by TAM treatment,
may therefore indicate the possibility of membrane damage
and interference with bile excretory mechanisms in the liver.
Micrographs for the TV and TAM groups also show some
degenerative changes and infiltration of inflammatory cells.
Data from the present study conform to that of a previous
study demonstrating a serum upsurge of ALP in LA7-induced
mammary tumorigenesis (Abbasalipourkabir et al., 2010). In
contrast, serum concentrations of ALP were lowered in the
E2 groups, although significant only in the E2S1000 group
(P < 0.01), suggesting a hepatoprotective effect of E2, supported
by micrographs showing normal liver architecture in this
treatment group.
Alanine aminotransferase and AST are found abundantly
in the cytosol of the hepatocyte and serum increases in these
enzymes are associated with hepatocellular injury and increased
membrane permeability (Solter, 2005). Elevation in serum levels
of ALT after E2 treatment for 4 weeks in the E2L1000 group
suggests damage to liver cells. In contrast, the reduction in
ALT and AST levels in the E2S100 group demonstrates the
hepatoprotective effect of E2. Collectively, the results suggest
a dose-dependent hepatotoxic effect of E2. Furthermore, the
significant elevation in the serum levels of ALT (P < 0.01) and
AST (P < 0.05) by LET in the current study suggests drug-
induced hepatocellular injury. FUL treatment, however, did not
alter the levels of liver injury biomarkers in comparison to TV
group.
Mammary tumor induction did not significantly affect
the lipid profile in the TV group relative to the CV
group. Furthermore, treatment with the phytoestrogenic extract,
SM6Met, did not significantly alter lipid profiles nor did the SOC
endocrine therapies. However, alteration in serum lipid profile
was observed with E2 treatment (Table 3). The mechanism of
estrogen-induced hypertriglyceridemia involves the promotion
of hepatic triglyceride synthesis and a reduction in the activity
of hepatic triglyceride lipase (Lee and Goldberg, 2008). Although
the effects of exogenous estrogens on the lipid profile are
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dependent on the dose, route of administration, and formulation
(Masood et al., 2010), they are generally characterized by a
decrease in total and low-density-lipoprotein cholesterol and an
increase in high-density-lipoprotein cholesterol and triglycerides
(Kavanagh et al., 2009). Furthermore, the results from the current
study are in line with the report on the cholesterol lowering effect
of estrogen in ovary intact female rats (Weinstein et al., 1986).
Contrary to clinical studies demonstrating the elevation of HDL-
cholesterol by estrogens, the reduction in serum concentration
of HDL-cholesterol in the present study may be due to species
differences between rats and humans. In the rat, 60% of the
circulating cholesterol is found in HDL and 30% in LDL, as
opposed to the 30% found in HDL and 60% found in LDL in
the human (Gwynne et al., 1976). The fact that HDL-cholesterol
is the main serum lipoprotein cholesterol in rats may explain
the significant reduction of HDL-cholesterol observed with E2
treatment in the current study.
CONCLUSION
The LA7 mammary tumor model is a relatively new orthotopic
method of tumor development that has the advantage of inducing
mammary tumor in a much shorter time than chemically induced
mammary tumor models (MNU and DMBA). The current study
is the first to report on the effects of E2 and SOC endocrine
drugs, such as FUL and LET, on the growth of LA7-induced
mammary tumors. Paradoxically, the protective effects of short-
term E2 treatment and endocrine therapy observed on tumor
growth in this model may occur via different mechanisms of
action (Rajkumar et al., 2007) and might indicate some level of E2
responsiveness. It might thus prove useful to evaluate the effects
of potential antitumor agents using ovariectomized rats in future
studies.
The tumor-suppressing effect of SM6Met in this study is
remarkable considering the highly tumorigenic and aggressive
growth of LA7-induced mammary tumors (Abbasalipourkabir
et al., 2010). Moreover, the chemopreventative action of SM6Met
is coupled to a significantly better safety profile than seen
with the SOC endocrine therapies and highlights its promising
potential for BC chemoprevention. Future studies will explore the
underlying mechanisms by which SM6Met delay tumor growth.
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FIGURE S1 | Time-course of mammary tumor progression in rats treated with
water (TW) or vehicle (TV). Points are indicative of mean tumor volume ± SEM.
Number of rats in TW (n = 8) and TV (n = 10). Statistical analysis was
performed using a paired two-tailed t-test and no significant difference was
observed.
FIGURE S2 | Time-course of percentage tumor inhibition (%TI). (A) SM6Met, (B)
SOC endocrine therapies (TAM, FUL, and LET), (C) E2, and (D) a comparison of
S500 with SOCs. Points are indicative of mean %TI. Statistical analysis for (D) was
performed using repeated measures ANOVA plus Dunnett’s post hoc test
comparing mean %TI time-course of all SOC treatments to S500. %TI
time-course of S500 was not significantly different from that of TAM but was
significantly different from that of FUL (P < ∗∗∗) and LET (P < ∗). Percentage tumor
inhibition (%TI) was calculated as: (Vc – Vt)/Vc × 100 (de Sousa et al., 2007),
where Vc and Vt are the mean tumor volumes of the negative control (group 3: TV)
and treatment groups (groups 4–13), respectively.
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